A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

Marek Trnĕný, Gregor Verhoef, Martin JS Dyer, Dina Ben Yehuda, Caterina Patti, Miguel Canales, Andrés Lopez, Farrukh T Awan, Paul G Montgomery, Andrea Janikova, Anna M Barbui, Kazimierz Sulek, Maria J Terol, John Radford, Anna Guidetti, Massimo Di Nicola, Laure Siraudin, Laurence Hatteville, Sandrine Schwab, Corina Oprea, Alessandro M Gianni

Open source

DOI: 10.3324/haematol.2017.168401
Published: 2018-05-10
Container: Haematologica
Publisher: Ferrata Storti Foundation (Haematologica)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2017.168401,
  title = {A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy},
  author = {Marek Trnĕný and Gregor Verhoef and Martin JS Dyer and Dina Ben Yehuda and Caterina Patti and Miguel Canales and Andrés Lopez and Farrukh T Awan and Paul G Montgomery and Andrea Janikova and Anna M Barbui and Kazimierz Sulek and Maria J Terol and John Radford and Anna Guidetti and Massimo Di Nicola and Laure Siraudin and Laurence Hatteville and Sandrine Schwab and Corina Oprea and Alessandro M Gianni},
  year = {2018},
  journal = {Haematologica},
  doi = {10.3324/haematol.2017.168401},
  url = {https://doi.org/10.3324/haematol.2017.168401}
}

RIS

TY  - JOUR
TI  - A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
AU  - Marek Trnĕný
AU  - Gregor Verhoef
AU  - Martin JS Dyer
AU  - Dina Ben Yehuda
AU  - Caterina Patti
AU  - Miguel Canales
AU  - Andrés Lopez
AU  - Farrukh T Awan
AU  - Paul G Montgomery
AU  - Andrea Janikova
AU  - Anna M Barbui
AU  - Kazimierz Sulek
AU  - Maria J Terol
AU  - John Radford
AU  - Anna Guidetti
AU  - Massimo Di Nicola
AU  - Laure Siraudin
AU  - Laurence Hatteville
AU  - Sandrine Schwab
AU  - Corina Oprea
AU  - Alessandro M Gianni
PY  - 2018
JO  - Haematologica
DO  - 10.3324/haematol.2017.168401
UR  - https://doi.org/10.3324/haematol.2017.168401
ER  -

APA

Trnĕný, M., Verhoef, G., Dyer, M. J., Yehuda, D. B., Patti, C., Canales, M., Lopez, A., Awan, F. T., Montgomery, P. G., Janikova, A., Barbui, A. M., Sulek, K., Terol, M. J., Radford, J., Guidetti, A., Nicola, M. D., Siraudin, L., Hatteville, L., Schwab, S., Oprea, C., & Gianni, A. M. (2018). A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. https://doi.org/10.3324/haematol.2017.168401

Source records

crossref · retrieved 2026-09-26T06:27:59.644Z